Senores Pharmaceuticals, Inc. has announced the commercial launch of Deferiprone Tablets USP in 500 mg and 1000 mg strengths in the United States. The newly introduced product is bioequivalent and therapeutically equivalent to Ferriprox Tablets, marketed by Chiesi USA, Inc., and will be distributed through Dr. Reddy’s Laboratories Inc., further strengthening Senores’ presence in the U.S. generics market.
The company emphasized that this launch represents a strategic milestone in its effort to expand into high-value, limited-competition therapeutic categories. Swapnil Shah, Managing Director of Senores Pharmaceuticals Limited, stated that the introduction of Deferiprone aligns with the company’s commitment to identifying niche and under-penetrated segments where access to cost-effective treatment options remains limited. He noted that the product is designed to support unmet clinical needs while contributing to the company’s long-term growth strategy.
Deferiprone is an important therapy for managing transfusional iron overload, especially in patients who require long-term treatment. Combined U.S. sales of branded and generic Deferiprone Tablets reached an estimated USD 70 million for the twelve months ending October 2025, according to Symphony data. With this entry, Senores aims to strengthen competition in the segment and provide a reliable, affordable option for healthcare providers and patients.
